These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20659271)

  • 1. Data generalizability, data transferability, and the political economy of pharmacoeconomic guidelines.
    Turk F
    Value Health; 2010 Dec; 13(8):863-4. PubMed ID: 20659271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What do international pharmacoeconomic guidelines say about economic data transferability?
    Barbieri M; Drummond M; Rutten F; Cook J; Glick HA; Lis J; Reed SD; Sculpher M; Severens JL;
    Value Health; 2010 Dec; 13(8):1028-37. PubMed ID: 20667054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
    Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
    Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The transferability of valuing lost productivity across jurisdictions. differences between national pharmacoeconomic guidelines.
    Knies S; Severens JL; Ament AJ; Evers SM
    Value Health; 2010 Aug; 13(5):519-27. PubMed ID: 20712601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI.
    Shi L; Hodges M; Drummond M; Ahn J; Li SC; Hu S; Augustovski F; Hay JW; Smeeding J
    Value Health; 2010; 13(1):28-33. PubMed ID: 19883403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging standardization in pharmacoeconomics.
    Mullins CD; Ogilvie S
    Clin Ther; 1998; 20(6):1194-202; discussion 1192-3. PubMed ID: 9916612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of pharmacoeconomic guidelines.
    Zhao Y; Feng HM; Qu J; Luo X; Ma WJ; Tian JH
    J Med Econ; 2018 Jan; 21(1):85-96. PubMed ID: 28959910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluations in European reimbursement submission guidelines: current status and comparisons.
    Bracco A; Krol M
    Expert Rev Pharmacoecon Outcomes Res; 2013 Oct; 13(5):579-95. PubMed ID: 24138645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
    Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
    Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II.
    Cox E; Martin BC; Van Staa T; Garbe E; Siebert U; Johnson ML
    Value Health; 2009; 12(8):1053-61. PubMed ID: 19744292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomics: an emerging discipline.
    Letizia C
    Qual Assur; 1995 Mar; 4(1):68-74. PubMed ID: 8520866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the quality of pharmacoeconomic evaluation literature in China.
    Zhang F; He X; Xiang W; Li SC
    J Med Econ; 2017 May; 20(5):510-517. PubMed ID: 28125918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomics--an aid to better decision-making.
    Arenas-Guzman R; Tosti A; Hay R; Haneke E;
    J Eur Acad Dermatol Venereol; 2005 Sep; 19 Suppl 1():34-9. PubMed ID: 16120204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.
    Clemens K; Townsend R; Luscombe F; Mauskopf J; Osterhaus J; Bobula J
    Pharmacoeconomics; 1995 Aug; 8(2):169-74. PubMed ID: 10155611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis.
    Bansback N; Maetzel A; Drummond M; Anis A; Marra C; Conway P; Boers M; Tugwell P; Boonen A
    J Rheumatol; 2007 May; 34(5):1178-83. PubMed ID: 17477483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How should we deal with patient heterogeneity in economic evaluation: a systematic review of national pharmacoeconomic guidelines.
    Ramaekers BL; Joore MA; Grutters JP
    Value Health; 2013; 16(5):855-62. PubMed ID: 23947981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transferability of Economic Evaluations of Treatments for Advanced Melanoma.
    Gorry C; McCullagh L; Barry M
    Pharmacoeconomics; 2020 Feb; 38(2):217-231. PubMed ID: 31761996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.